Institution
Aix-Marseille University
Education•Marseille, France•
About: Aix-Marseille University is a education organization based out in Marseille, France. It is known for research contribution in the topics: Population & Galaxy. The organization has 24326 authors who have published 54240 publications receiving 1455416 citations. The organization is also known as: University Aix-Marseille & université d'Aix-Marseille.
Topics: Population, Galaxy, Context (language use), Redshift, Medicine
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The physicochemical basis for mitochondrial accumulation of lipophilic cations, synthetic chemistry strategies to target compounds to mitochondria, mitochondrial probes, and sensors, and examples of mitochondrial targeting of bioactive compounds are described.
Abstract: Mitochondria are recognized as one of the most important targets for new drug design in cancer, cardiovascular, and neurological diseases. Currently, the most effective way to deliver drugs specifically to mitochondria is by covalent linking a lipophilic cation such as an alkyltriphenylphosphonium moiety to a pharmacophore of interest. Other delocalized lipophilic cations, such as rhodamine, natural and synthetic mitochondria-targeting peptides, and nanoparticle vehicles, have also been used for mitochondrial delivery of small molecules. Depending on the approach used, and the cell and mitochondrial membrane potentials, more than 1000-fold higher mitochondrial concentration can be achieved. Mitochondrial targeting has been developed to study mitochondrial physiology and dysfunction and the interaction between mitochondria and other subcellular organelles and for treatment of a variety of diseases such as neurodegeneration and cancer. In this Review, we discuss efforts to target small-molecule compounds to mitochondria for probing mitochondria function, as diagnostic tools and potential therapeutics. We describe the physicochemical basis for mitochondrial accumulation of lipophilic cations, synthetic chemistry strategies to target compounds to mitochondria, mitochondrial probes, and sensors, and examples of mitochondrial targeting of bioactive compounds. Finally, we review published attempts to apply mitochondria-targeted agents for the treatment of cancer and neurodegenerative diseases.
892 citations
••
University of Toronto1, University of Colorado Boulder2, Pierre-and-Marie-Curie University3, University of Oxford4, University of Paris5, Centre national de la recherche scientifique6, Aix-Marseille University7, INAF8, Las Cumbres Observatory Global Telescope Network9, University of California, Santa Barbara10, Defence Research and Development Canada11, University of Victoria12, California Institute of Technology13, Centra14, Lawrence Berkeley National Laboratory15, University of Waterloo16, Australian Astronomical Observatory17, University of California, Berkeley18
TL;DR: In this article, the authors combine high redshift Type Ia supernovae from the first 3 years of the Supernova Legacy Survey (SNLS) with other supernova (SN) samples, primarily at lower redshifts, to form a high-quality joint sample of 472 SNe (123 low-$z, 93 SDSS, 242 SNLS, and 14 {\it Hubble Space Telescope}).
Abstract: We combine high redshift Type Ia supernovae from the first 3 years of the Supernova Legacy Survey (SNLS) with other supernova (SN) samples, primarily at lower redshifts, to form a high-quality joint sample of 472 SNe (123 low-$z$, 93 SDSS, 242 SNLS, and 14 {\it Hubble Space Telescope}). SN data alone require cosmic acceleration at >99.9% confidence, including systematic effects. For the dark energy equation of state parameter (assumed constant out to at least $z=1.4$) in a flat universe, we find $w = -0.91^{+0.16}_{-0.20}(\mathrm{stat}) ^{+0.07}_{-0.14} (\mathrm{sys})$ from SNe only, consistent with a cosmological constant. Our fits include a correction for the recently discovered relationship between host-galaxy mass and SN absolute brightness. We pay particular attention to systematic uncertainties, characterizing them using a systematics covariance matrix that incorporates the redshift dependence of these effects, as well as the shape-luminosity and color-luminosity relationships. Unlike previous work, we include the effects of systematic terms on the empirical light-curve models. The total systematic uncertainty is dominated by calibration terms. We describe how the systematic uncertainties can be reduced with soon to be available improved nearby and intermediate-redshift samples, particularly those calibrated onto USNO/SDSS-like systems.
889 citations
••
Washington University in St. Louis1, Rush University Medical Center2, University of California, San Francisco3, University of Cambridge4, University of Cincinnati5, University of California, Los Angeles6, Aix-Marseille University7, Columbia University8, University of Virginia9, University of Düsseldorf10, University of Florida11, Mayo Clinic12, University of Pennsylvania13, Innsbruck Medical University14, University of Milan15, Baylor College of Medicine16, Nottingham University Hospitals NHS Trust17, Utrecht University18, Free University of Berlin19
TL;DR: Recommendations were developed based on literature review using the GRADE system, discussion integrating the literature with the collective experience of the participants and critical review by an impartial jury and emphasis was placed on the principle that recommendations should be based not only on the quality of the data but also tradeoffs and translation into practice.
Abstract: Subarachnoid hemorrhage (SAH) is an acute cerebrovascular event which can have devastating effects on the central nervous system as well as a profound impact on several other organs SAH patients are routinely admitted to an intensive care unit and are cared for by a multidisciplinary team A lack of high quality data has led to numerous approaches to management and limited guidance on choosing among them Existing guidelines emphasize risk factors, prevention, natural history, and prevention of rebleeding, but provide limited discussion of the complex critical care issues involved in the care of SAH patients The Neurocritical Care Society organized an international, multidisciplinary consensus conference on the critical care management of SAH to address this need Experts from neurocritical care, neurosurgery, neurology, interventional neuroradiology, and neuroanesthesiology from Europe and North America were recruited based on their publications and expertise A jury of four experienced neurointensivists was selected for their experience in clinical investigations and development of practice guidelines Recommendations were developed based on literature review using the GRADE system, discussion integrating the literature with the collective experience of the participants and critical review by an impartial jury Recommendations were developed using the GRADE system Emphasis was placed on the principle that recommendations should be based not only on the quality of the data but also tradeoffs and translation into practice Strong consideration was given to providing guidance and recommendations for all issues faced in the daily management of SAH patients, even in the absence of high quality data
884 citations
••
TL;DR: The extent of the trait data compiled in TRY is evaluated and emerging patterns of data coverage and representativeness are analyzed to conclude that reducing data gaps and biases in the TRY database remains a key challenge and requires a coordinated approach to data mobilization and trait measurements.
Abstract: Plant traits-the morphological, anatomical, physiological, biochemical and phenological characteristics of plants-determine how plants respond to environmental factors, affect other trophic levels, and influence ecosystem properties and their benefits and detriments to people. Plant trait data thus represent the basis for a vast area of research spanning from evolutionary biology, community and functional ecology, to biodiversity conservation, ecosystem and landscape management, restoration, biogeography and earth system modelling. Since its foundation in 2007, the TRY database of plant traits has grown continuously. It now provides unprecedented data coverage under an open access data policy and is the main plant trait database used by the research community worldwide. Increasingly, the TRY database also supports new frontiers of trait-based plant research, including the identification of data gaps and the subsequent mobilization or measurement of new data. To support this development, in this article we evaluate the extent of the trait data compiled in TRY and analyse emerging patterns of data coverage and representativeness. Best species coverage is achieved for categorical traits-almost complete coverage for 'plant growth form'. However, most traits relevant for ecology and vegetation modelling are characterized by continuous intraspecific variation and trait-environmental relationships. These traits have to be measured on individual plants in their respective environment. Despite unprecedented data coverage, we observe a humbling lack of completeness and representativeness of these continuous traits in many aspects. We, therefore, conclude that reducing data gaps and biases in the TRY database remains a key challenge and requires a coordinated approach to data mobilization and trait measurements. This can only be achieved in collaboration with other initiatives.
882 citations
••
University of Texas MD Anderson Cancer Center1, City of Hope National Medical Center2, Duke University3, Royal Melbourne Hospital4, Indiana University5, Harvard University6, University of Adelaide7, Princess Margaret Cancer Centre8, Fox Chase Cancer Center9, Seoul National University10, Roswell Park Cancer Institute11, University of Michigan12, University of Washington13, Sungkyunkwan University14, University of Ulsan15, Aix-Marseille University16, University of California, San Francisco17, Emory University18, University of Pittsburgh19, Amgen20, Cornell University21, Washington University in St. Louis22
TL;DR: Sotorasib showed encouraging anticancer activity in patients with heavily pretreated advanced solid tumors harboring the KRAS p.G12C mutation and responded to pharmacokinetics and objective response according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.
Abstract: Background No therapies for targeting KRAS mutations in cancer have been approved. The KRAS p.G12C mutation occurs in 13% of non–small-cell lung cancers (NSCLCs) and in 1 to 3% of colorect...
882 citations
Authors
Showing all 24784 results
Name | H-index | Papers | Citations |
---|---|---|---|
Didier Raoult | 173 | 3267 | 153016 |
Andrea Bocci | 172 | 2402 | 176461 |
Marc Humbert | 149 | 1184 | 100577 |
Carlo Rovelli | 146 | 1502 | 103550 |
Marc Besancon | 143 | 1799 | 106869 |
Jian Yang | 142 | 1818 | 111166 |
Josh Moss | 139 | 1019 | 89255 |
Maksym Titov | 139 | 1573 | 128335 |
Bernard Henrissat | 139 | 593 | 100002 |
R. D. Kass | 138 | 1920 | 107907 |
Stylianos E. Antonarakis | 138 | 746 | 93605 |
Jean-Paul Kneib | 138 | 805 | 89287 |
Brad Abbott | 137 | 1566 | 98604 |
Shu Li | 136 | 1001 | 78390 |
Georges Aad | 135 | 1121 | 88811 |